PMID- 34976837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With 
      Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and 
      Meta-Analysis.
PG  - 795650
LID - 10.3389/fonc.2021.795650 [doi]
LID - 795650
AB  - BACKGROUND: It is still controversial whether immune checkpoint inhibitors (ICIs) 
      can improve the curative effect when added to original standard chemotherapy 
      treatment for triple-negative breast cancer (TNBC). We compared their antitumor 
      efficacy and adverse effects (AEs) to make a better clinical decision. METHODS: 
      Seven databases were searched for eligible articles. Progression-free survival 
      (PFS), overall survival (OS), and AEs were measured as the primary outcomes. 
      RESULTS: Nine randomized controlled trials (RCTs) involving 4,501 patients were 
      included. ICI+chemotherapy treatment achieved better PFS (hazard ratio [HR]: 
      0.78, [0.70-0.86], p < 0.00001), OS (HR: 0.86, [0.74-0.99], p = 0.04), and 
      complete response (584/1,106 vs. 341/825, risk ratio [RR]: 1.38, [1.01-1.89], p = 
      0.04). With the prolongation of survival, the survival advantage of 
      ICI+chemotherapy increased compared with chemotherapy. Subgroup analysis 
      suggested that the addition of ICIs might not have a better effect in Asian 
      patients, patients with locally advanced disease, or patients with brain 
      metastases. In the toxicity analysis, more Grade 3-5 AEs and serious AEs were 
      found in the ICI+chemotherapy group. For Grade 3-5 AEs, more cases of diarrhea, 
      severe skin reactions, pneumonitis, hepatitis, and adrenal insufficiency were 
      related to the ICI+chemotherapy group. CONCLUSIONS: ICI+chemotherapy appears to 
      be better than chemotherapy alone for TNBC treatment, with better OS and PFS. 
      However, its high rates of serious AEs need to be taken seriously. SYSTEMATIC 
      REVIEW REGISTRATION: PROSPERO Registration: CRD42021276394.
CI  - Copyright (c) 2021 Ji, Ding, Hao, Luo, Huang and Zhang.
FAU - Ji, Qiao
AU  - Ji Q
AD  - Department of Radiation Oncology, The Third Hospital of Nanchang, Nanchang, 
      China.
FAU - Ding, Jingxian
AU  - Ding J
AD  - Department of Radiation Oncology, The Third Hospital of Nanchang, Nanchang, 
      China.
FAU - Hao, Meiqi
AU  - Hao M
AD  - Department of Breast surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Luo, Nachuan
AU  - Luo N
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Huang, Jiabing
AU  - Huang J
AD  - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Systematic Review
DEP - 20211216
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8716854
OTO - NOTNLM
OT  - chemotherapy
OT  - immune checkpoint inhibitors
OT  - meta-analysis
OT  - systematic review
OT  - triple-negative breast cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/01/01
CRDT- 2022/01/03 05:47
PHST- 2021/10/15 00:00 [received]
PHST- 2021/11/22 00:00 [accepted]
PHST- 2022/01/03 05:47 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.795650 [doi]
PST - epublish
SO  - Front Oncol. 2021 Dec 16;11:795650. doi: 10.3389/fonc.2021.795650. eCollection 
      2021.